Eur Rev Med Pharmacol Sci 2020; 24 (2): 983-987

DOI: 10.26355/eurrev_202001_20084

Editorial – HCC in HCV patients and the direct acting antivirals: is there really a link?

A. Marrone, G. Franci, A. Perrella, R. Nevola, A. Chianese, L.E. Adinolfi, F.C. Sasso, L. Rinaldi

Department of Advanced Surgical and Medical Sciences, University of Campania Luigi Vanvitelli, Naples, Italy. lucarinaldi@hotmail.it

Free PDF Download

To cite this article

A. Marrone, G. Franci, A. Perrella, R. Nevola, A. Chianese, L.E. Adinolfi, F.C. Sasso, L. Rinaldi
Editorial – HCC in HCV patients and the direct acting antivirals: is there really a link?

Eur Rev Med Pharmacol Sci
Year: 2020
Vol. 24 - N. 2
Pages: 983-987
DOI: 10.26355/eurrev_202001_20084

Keywords Related articles:

  1. Editorial – Sofosbuvir/Velpatasvir as a combination with strong potential activity against SARS-CoV2 (COVID-19) infection: how to use direct-acting antivirals as broad-spectrum antiviral agents
  2. Primary biliary cholangitis development after hepatitis C virus eradication with direct acting antivirals: a case report and review of the literature
  3. Optimising management of patients with hepatitis C virus in the age of direct-acting antivirals: results of a Delphi consensus
  4. Impact of reimbursement limits on patient access to direct-acting antivirals in Italy: analysis of data from national registries
  5. Gastroesophageal reflux disease. Are we acting in the best interest of our patients?